Clinical Progress
Nventa originally advanced HspE7 as a single-agent therapy into multiple Phase 2 clinical trials with positive results, including trials in cervical dysplasia and recurrent respiratory papillomatosis (RRP). These trials were initiated prior to the discovery that potency could be greatly enhanced by addition of a vaccine adjuvant. Nventa is currently developing HspE7 combined with the TH1-directed adjuvant Poly-ICLC. A Phase 1b study is complete, assessing safety and tolerability in 17 patients with CIN.
Read more about this topic: Nventa Biopharmaceuticals Corporation
Famous quotes containing the word progress:
“Whatever there be of progress in life comes not through adaptation but through daring, through obeying the blind urge.”
—Henry Miller (1891–1980)